Cargando…

Herpesviruses Serology Distinguishes Different Subgroups of Patients From the United Kingdom Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Biobank

The evidence of an association between Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and chronic herpesviruses infections remains inconclusive. Two reasons for the lack of consistent evidence are the large heterogeneity of the patients' population with different disease triggers a...

Descripción completa

Detalles Bibliográficos
Autores principales: Domingues, Tiago Dias, Grabowska, Anna D., Lee, Ji-Sook, Ameijeiras-Alonso, Jose, Westermeier, Francisco, Scheibenbogen, Carmen, Cliff, Jacqueline M., Nacul, Luis, Lacerda, Eliana M., Mouriño, Helena, Sepúlveda, Nuno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287507/
https://www.ncbi.nlm.nih.gov/pubmed/34291062
http://dx.doi.org/10.3389/fmed.2021.686736
_version_ 1783723920931684352
author Domingues, Tiago Dias
Grabowska, Anna D.
Lee, Ji-Sook
Ameijeiras-Alonso, Jose
Westermeier, Francisco
Scheibenbogen, Carmen
Cliff, Jacqueline M.
Nacul, Luis
Lacerda, Eliana M.
Mouriño, Helena
Sepúlveda, Nuno
author_facet Domingues, Tiago Dias
Grabowska, Anna D.
Lee, Ji-Sook
Ameijeiras-Alonso, Jose
Westermeier, Francisco
Scheibenbogen, Carmen
Cliff, Jacqueline M.
Nacul, Luis
Lacerda, Eliana M.
Mouriño, Helena
Sepúlveda, Nuno
author_sort Domingues, Tiago Dias
collection PubMed
description The evidence of an association between Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and chronic herpesviruses infections remains inconclusive. Two reasons for the lack of consistent evidence are the large heterogeneity of the patients' population with different disease triggers and the use of arbitrary cutoffs for defining seropositivity. In this work we re-analyzed previously published serological data related to 7 herpesvirus antigens. Patients with ME/CFS were subdivided into four subgroups related to the disease triggers: S(0)-42 patients who did not know their disease trigger; S(1)-43 patients who reported a non-infection trigger; S(2)-93 patients who reported an infection trigger, but that infection was not confirmed by a lab test; and S(3)-48 patients who reported an infection trigger and that infection was confirmed by a lab test. In accordance with a sensitivity analysis, the data were compared to those from 99 healthy controls allowing the seropositivity cutoffs to vary within a wide range of possible values. We found a negative association between S(1) and seropositivity to Epstein-Barr virus (VCA and EBNA1 antigens) and Varicella-Zoster virus using specific seropositivity cutoff. However, this association was not significant when controlling for multiple testing. We also found that S(3) had a lower seroprevalence to the human cytomegalovirus when compared to healthy controls for all cutoffs used for seropositivity and after adjusting for multiple testing using the Benjamini-Hochberg procedure. However, this association did not reach statistical significance when using Benjamini-Yekutieli procedure. In summary, herpesviruses serology could distinguish subgroups of ME/CFS patients according to their disease trigger, but this finding could be eventually affected by the problem of multiple testing.
format Online
Article
Text
id pubmed-8287507
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82875072021-07-20 Herpesviruses Serology Distinguishes Different Subgroups of Patients From the United Kingdom Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Biobank Domingues, Tiago Dias Grabowska, Anna D. Lee, Ji-Sook Ameijeiras-Alonso, Jose Westermeier, Francisco Scheibenbogen, Carmen Cliff, Jacqueline M. Nacul, Luis Lacerda, Eliana M. Mouriño, Helena Sepúlveda, Nuno Front Med (Lausanne) Medicine The evidence of an association between Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and chronic herpesviruses infections remains inconclusive. Two reasons for the lack of consistent evidence are the large heterogeneity of the patients' population with different disease triggers and the use of arbitrary cutoffs for defining seropositivity. In this work we re-analyzed previously published serological data related to 7 herpesvirus antigens. Patients with ME/CFS were subdivided into four subgroups related to the disease triggers: S(0)-42 patients who did not know their disease trigger; S(1)-43 patients who reported a non-infection trigger; S(2)-93 patients who reported an infection trigger, but that infection was not confirmed by a lab test; and S(3)-48 patients who reported an infection trigger and that infection was confirmed by a lab test. In accordance with a sensitivity analysis, the data were compared to those from 99 healthy controls allowing the seropositivity cutoffs to vary within a wide range of possible values. We found a negative association between S(1) and seropositivity to Epstein-Barr virus (VCA and EBNA1 antigens) and Varicella-Zoster virus using specific seropositivity cutoff. However, this association was not significant when controlling for multiple testing. We also found that S(3) had a lower seroprevalence to the human cytomegalovirus when compared to healthy controls for all cutoffs used for seropositivity and after adjusting for multiple testing using the Benjamini-Hochberg procedure. However, this association did not reach statistical significance when using Benjamini-Yekutieli procedure. In summary, herpesviruses serology could distinguish subgroups of ME/CFS patients according to their disease trigger, but this finding could be eventually affected by the problem of multiple testing. Frontiers Media S.A. 2021-07-05 /pmc/articles/PMC8287507/ /pubmed/34291062 http://dx.doi.org/10.3389/fmed.2021.686736 Text en Copyright © 2021 Domingues, Grabowska, Lee, Ameijeiras-Alonso, Westermeier, Scheibenbogen, Cliff, Nacul, Lacerda, Mouriño and Sepúlveda. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Domingues, Tiago Dias
Grabowska, Anna D.
Lee, Ji-Sook
Ameijeiras-Alonso, Jose
Westermeier, Francisco
Scheibenbogen, Carmen
Cliff, Jacqueline M.
Nacul, Luis
Lacerda, Eliana M.
Mouriño, Helena
Sepúlveda, Nuno
Herpesviruses Serology Distinguishes Different Subgroups of Patients From the United Kingdom Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Biobank
title Herpesviruses Serology Distinguishes Different Subgroups of Patients From the United Kingdom Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Biobank
title_full Herpesviruses Serology Distinguishes Different Subgroups of Patients From the United Kingdom Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Biobank
title_fullStr Herpesviruses Serology Distinguishes Different Subgroups of Patients From the United Kingdom Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Biobank
title_full_unstemmed Herpesviruses Serology Distinguishes Different Subgroups of Patients From the United Kingdom Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Biobank
title_short Herpesviruses Serology Distinguishes Different Subgroups of Patients From the United Kingdom Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Biobank
title_sort herpesviruses serology distinguishes different subgroups of patients from the united kingdom myalgic encephalomyelitis/chronic fatigue syndrome biobank
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287507/
https://www.ncbi.nlm.nih.gov/pubmed/34291062
http://dx.doi.org/10.3389/fmed.2021.686736
work_keys_str_mv AT dominguestiagodias herpesvirusesserologydistinguishesdifferentsubgroupsofpatientsfromtheunitedkingdommyalgicencephalomyelitischronicfatiguesyndromebiobank
AT grabowskaannad herpesvirusesserologydistinguishesdifferentsubgroupsofpatientsfromtheunitedkingdommyalgicencephalomyelitischronicfatiguesyndromebiobank
AT leejisook herpesvirusesserologydistinguishesdifferentsubgroupsofpatientsfromtheunitedkingdommyalgicencephalomyelitischronicfatiguesyndromebiobank
AT ameijeirasalonsojose herpesvirusesserologydistinguishesdifferentsubgroupsofpatientsfromtheunitedkingdommyalgicencephalomyelitischronicfatiguesyndromebiobank
AT westermeierfrancisco herpesvirusesserologydistinguishesdifferentsubgroupsofpatientsfromtheunitedkingdommyalgicencephalomyelitischronicfatiguesyndromebiobank
AT scheibenbogencarmen herpesvirusesserologydistinguishesdifferentsubgroupsofpatientsfromtheunitedkingdommyalgicencephalomyelitischronicfatiguesyndromebiobank
AT cliffjacquelinem herpesvirusesserologydistinguishesdifferentsubgroupsofpatientsfromtheunitedkingdommyalgicencephalomyelitischronicfatiguesyndromebiobank
AT naculluis herpesvirusesserologydistinguishesdifferentsubgroupsofpatientsfromtheunitedkingdommyalgicencephalomyelitischronicfatiguesyndromebiobank
AT lacerdaelianam herpesvirusesserologydistinguishesdifferentsubgroupsofpatientsfromtheunitedkingdommyalgicencephalomyelitischronicfatiguesyndromebiobank
AT mourinohelena herpesvirusesserologydistinguishesdifferentsubgroupsofpatientsfromtheunitedkingdommyalgicencephalomyelitischronicfatiguesyndromebiobank
AT sepulvedanuno herpesvirusesserologydistinguishesdifferentsubgroupsofpatientsfromtheunitedkingdommyalgicencephalomyelitischronicfatiguesyndromebiobank